Darbufelone (mesylate)

$150$1,550

Products Details

Product Description

– Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF2α and LTB4 production. Darbufelone potently inhibits PGHS-2 (IC50 = 0.19 μM) but is much less potent with PGHS-1 (IC50= 20 μM).

Web ID

– HY-101438A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture and light)

Shipping

– Room Temperature

Applications

– Metabolism-protein/nucleotide metabolism

Molecular Formula

– C19H28N2O5S2

References

– [1]Johnson AR, et al. Slow-binding inhibition of human prostaglandin endoperoxide synthase-2 with darbufelone, an isoform-selective antiinflammatory di-tert-butyl phenol. Biochemistry. 2001 Jun 26;40(25):7736-45.|[2]Ye X, et al. Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo. Cancer Chemother Pharmacol. 2010 Jul;66(2):277-85.

CAS Number

– 139340-56-0

Molecular Weight

– 428.57

Compound Purity

– 98.45

SMILES

– O=C1N=C(N)S/C1=CC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2.CS(=O)(O)=O

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology; Endocrinology

Solubility

– DMSO : 110 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– Leukotriene Receptor;Prostaglandin Receptor

Isoform

– FP;LTB4

Pathway

– GPCR/G Protein

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=